Mounjaro for Sleep Apnea: Evidence, Off-Label Status, and Monitoring

What Is Mounjaro and Why Is It Being Used for Sleep Apnea?

Mounjaro (tirzepatide) is a once-weekly injectable medication that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The FDA approved it for type 2 diabetes in May 2022 and, under the brand name Zepbound, for chronic weight management in November 2023. Using it specifically for obstructive sleep apnea (OSA) is off-label.

The rationale for the sleep apnea application is straightforward. Obesity is the single largest modifiable risk factor for OSA, and losing 10% of body weight can reduce the apnea-hypopnea index (AHI) by approximately 26% in some patients, according to data published in the New England Journal of Medicine (NEJM Sleep Apnea and Weight Loss) [1]. Because tirzepatide produces significantly greater weight loss than older agents, researchers hypothesized it might produce clinically meaningful AHI reductions.

How Tirzepatide Produces Weight Loss

Tirzepatide suppresses appetite through at least two parallel mechanisms: GLP-1 receptor activation slows gastric emptying and reduces caloric intake, while GIP receptor activation appears to enhance the GLP-1 signal and may independently affect adipose tissue metabolism. In the SURMOUNT-1 trial (N=2,539), participants without diabetes lost a mean of 20.9% of body weight at 72 weeks on the 15 mg dose versus 3.1% on placebo (P<0.001) [2].

Why Weight Loss Matters for Airway Physiology

Fat deposits around the pharynx, tongue, and soft palate narrow the upper airway during sleep. Reducing that adipose load decreases the collapsibility of the airway, a property measured by the critical closing pressure (Pcrit). Lower Pcrit values correlate directly with fewer apneic events per hour. This mechanistic pathway is why the SURMOUNT-OSA investigators predicted that the weight loss magnitude achievable with tirzepatide would translate to large AHI reductions.

SURMOUNT-OSA: The Core Trial Evidence

SURMOUNT-OSA consists of two parallel, phase 3, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in June 2024 (NEJM SURMOUNT-OSA) [3]. Trial 1 enrolled adults who were not using CPAP (N=234). Trial 2 enrolled adults who were established CPAP users (N=235). Both trials ran for 52 weeks and used tirzepatide 10 mg or 15 mg (dose-escalated from 2.5 mg).

Primary Endpoint: AHI Change

The primary endpoint in both trials was the change from baseline in AHI (events per hour). Results were striking.

In Trial 1 (no CPAP), tirzepatide reduced AHI by a mean of 25.3 events per hour versus a reduction of 5.3 events per hour with placebo. That is a placebo-adjusted difference of approximately 20 events per hour (P<0.001) [3].

In Trial 2 (CPAP users), tirzepatide reduced AHI by 29.3 events per hour versus 5.5 events per hour with placebo, a placebo-adjusted difference of roughly 23.8 events per hour (P<0.001) [3].

These reductions moved a substantial proportion of participants from moderate-to-severe OSA categories into the mild or resolved categories by the end of the study.

Secondary Endpoints Worth Knowing

Beyond AHI, SURMOUNT-OSA tracked several patient-relevant outcomes.

• Hypoxic burden (the area under the oxygen desaturation curve) fell significantly in the tirzepatide group across both trials.
• Patient-reported sleepiness, measured by the Epworth Sleepiness Scale, improved by approximately 3 to 4 points versus placebo.
• C-reactive protein, systolic blood pressure, and waist circumference all improved more in the tirzepatide arm than in the placebo arm.

The NEJM authors noted that "tirzepatide significantly reduced the severity of obstructive sleep apnea and body weight in persons with obesity," with the caveat that longer-term data and head-to-head CPAP comparisons are still needed [3].

Weight Loss Achieved in SURMOUNT-OSA

Participants in the tirzepatide arms lost approximately 18 to 20% of body weight over 52 weeks, consistent with the SURMOUNT-1 and SURMOUNT-2 data in broader obesity populations [2, 4]. The correlation between weight lost and AHI reduction was strong (r approximately 0.6), suggesting the airway benefit is substantially mediated by fat loss rather than any direct drug effect on upper airway muscle tone.

Off-Label Status: What This Means Clinically

As of January 2025, the FDA has not approved tirzepatide for the indication of obstructive sleep apnea. The label for Mounjaro covers type 2 diabetes only. The label for Zepbound covers chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity.

Prescribing Mounjaro or Zepbound with a primary therapeutic goal of treating OSA is therefore an off-label prescription. Off-label prescribing is legal in the United States and common in clinical medicine. The FDA explicitly states that "healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient" (FDA Off-Label Use Guidance) [5].

GRADE Evidence Assessment

Using the GRADE framework, the current evidence for tirzepatide in OSA would be rated as moderate quality. The reasons are:

• Two phase 3 RCTs provide consistent, replicable results with large effect sizes (evidence upgrade factor).
• Both trials were funded by Eli Lilly and conducted over 52 weeks only, with no independent replication yet (downgrade for risk of bias and short duration).
• The trials excluded severe cardiovascular disease, so generalizability to high-risk OSA patients is uncertain (downgrade for indirectness).
• No active comparator arm (head-to-head versus CPAP) exists in the current data.

A GRADE moderate rating means clinicians can reasonably offer this treatment while being transparent about the limitations.

Insurance and Reimbursement Implications

Most commercial insurance plans and Medicare Part D do not cover Zepbound or Mounjaro for an OSA diagnosis alone. Coverage typically requires the diabetes or obesity indication to be the primary coded diagnosis. Patients pursuing tirzepatide primarily for OSA should expect to document their weight-related diagnosis (obesity, BMI 30 or higher) as the primary indication to maximize coverage probability. Prior authorization is almost universally required.

Monitoring Requirements for Tirzepatide in OSA Patients

Using tirzepatide off-label for OSA requires more active monitoring than using it purely for weight management, because the clinician is claiming a therapeutic effect on a separate physiologic system. The HealthRX medical team recommends the following structured monitoring protocol, developed from the SURMOUNT-OSA trial procedures, the American Academy of Sleep Medicine clinical practice guidelines (AASM) [6], and the Endocrine Society obesity pharmacotherapy guidelines (Endocrine Society) [7].

Baseline Assessment (Before Starting Tirzepatide)

Before the first dose, the following should be documented:

1. Polysomnography or validated home sleep apnea test (HSAT) confirming OSA diagnosis and establishing baseline AHI. AASM guidelines define moderate OSA as AHI 15 to 29.9 events per hour and severe as 30 or more events per hour [6].
2. Body weight and BMI, with confirmation of obesity classification.
3. Epworth Sleepiness Scale (ESS) score to document subjective daytime sleepiness.
4. Fasting glucose and HbA1c to screen for undiagnosed diabetes (relevant because tirzepatide lowers glucose and hypoglycemia management may change if the patient is also on insulin secretagogues).
5. Lipase and amylase if there is any history of pancreatitis.
6. Personal or family history of medullary thyroid carcinoma or MEN2, which are contraindications to all GLP-1-class drugs per the FDA label [8].
7. Current CPAP usage and adherence data (download from device if available).

Monitoring at 12 Weeks

At the 3-month mark, assess:

• Weight and percentage body weight lost from baseline.
• ESS score repeat.
• Tolerability of the dose-escalation schedule (patients typically reach 5 mg by week 8 and 10 mg by week 16 in standard protocols).
• Any gastrointestinal adverse events requiring dose adjustment or delay.
• CPAP download if applicable, as AHI on CPAP may begin to fall, prompting pressure re-titration.

The SURMOUNT-OSA protocols showed that statistically significant AHI reductions were detectable by week 24 [3], so the 12-week visit is primarily a safety and tolerability checkpoint rather than an efficacy evaluation.

Repeat Sleep Study at 6 to 12 Months

A repeat polysomnography or HSAT at 6 months (or by 12 months at the latest) is necessary to objectively quantify the OSA response. This is the step most often skipped in routine weight management practice but is non-negotiable when tirzepatide is being used with OSA as a therapeutic target.

A clinically meaningful AHI response is generally defined as a 50% or greater reduction in AHI, or movement from a more severe OSA category to a milder one. If a patient's AHI has dropped below 5 events per hour (effectively resolved OSA), the supervising sleep physician may consider suspending CPAP therapy under a structured CPAP discontinuation protocol with close follow-up.

Patients who do not achieve at least a 25% AHI reduction by 12 months despite 5 to 10% body weight loss should continue CPAP and reassess the overall treatment plan.

Ongoing Annual Monitoring

Annual monitoring should include:

• Repeat HSAT or in-lab polysomnography.
• Weight trajectory to confirm sustained loss.
• Thyroid function if clinically indicated (tirzepatide has not been shown to cause thyroid cancer in humans, but animal data prompted an FDA black-box warning about medullary thyroid carcinoma risk) [8].
• Gallstone screening if the patient develops right upper quadrant pain (rapid weight loss accelerates gallstone formation; the SURMOUNT-1 trial reported cholelithiasis in 1.2% of tirzepatide participants versus 0.4% placebo) [2].

How Tirzepatide Compares to CPAP and Other OSA Treatments

CPAP remains the first-line, gold-standard therapy for moderate-to-severe OSA, per both AASM and the American Academy of Otolaryngology guidelines. Tirzepatide does not replace CPAP in any current guideline.

The distinction between the two treatments matters. CPAP acts immediately, splinting the airway open during every breath, and reduces AHI to near zero in most adherent users. Tirzepatide works slowly, requiring months of weight loss before airway anatomy improves, and the AHI reduction, while large in absolute terms, leaves most patients still with measurable residual OSA at 52 weeks.

Where tirzepatide may add value is in the large population of patients who cannot tolerate CPAP. Estimates from the AASM suggest that 30 to 50% of OSA patients do not use CPAP consistently (fewer than 4 hours per night on fewer than 70% of nights) (AASM adherence data) [9]. For this group, a pharmacologic approach that reduces AHI by 20 to 25 events per hour could meaningfully lower cardiovascular risk even if it does not eliminate OSA entirely.

Comparison with Semaglutide for OSA

Semaglutide (Ozempic, Wegovy) also produces weight loss and has been studied in OSA. The SCALE Sleep Apnea trial showed that liraglutide 3 mg reduced AHI by approximately 12 events per hour over 32 weeks (N=359) (PubMed SCALE Sleep) [10]. Tirzepatide's reductions of 25 to 29 events per hour appear larger, consistent with its greater weight loss efficacy. Head-to-head trials between tirzepatide and semaglutide in OSA populations have not yet been published.

Oral Appliances and Surgical Options

Mandibular advancement devices are an alternative for mild-to-moderate OSA in patients who cannot tolerate CPAP, per AASM guidance [6]. Surgical options such as uvulopalatopharyngoplasty (UPPP) or hypoglossal nerve stimulation (Inspire therapy) may be appropriate for anatomically selected patients. Tirzepatide does not preclude any of these approaches and can be combined with them when obesity is a co-driver of the patient's OSA.

Patient Selection: Who Is a Candidate for Tirzepatide in OSA?

Not every patient with OSA and obesity is an appropriate candidate for tirzepatide as an OSA-directed therapy. The profile most likely to benefit, based on SURMOUNT-OSA inclusion criteria and mechanistic reasoning, includes:

• BMI 30 or higher (required for Zepbound approval; patients with BMI 27 to 29.9 require a documented weight-related comorbidity).
• Moderate-to-severe OSA (AHI 15 or higher on baseline sleep study).
• Either CPAP-intolerant or already on CPAP but seeking to reduce dependence.
• No personal or family history of medullary thyroid carcinoma or MEN2.
• No history of pancreatitis or severe gastroparesis.
• Not pregnant and not planning pregnancy within the treatment period (teratogenicity data are limited; the FDA label advises discontinuation at least 2 months before planned conception) [8].

Patients with mild OSA (AHI <15) are less likely to see a clinically relevant benefit from AHI reduction alone, though they may still benefit from weight loss for other metabolic reasons.

Dosing Schedule Used in SURMOUNT-OSA

The SURMOUNT-OSA trials used a standard dose-escalation schedule beginning at 2.5 mg once weekly, increasing by 2.5 mg increments every 4 weeks to a maintenance dose of 10 mg or 15 mg. This schedule mirrors the FDA-approved titration for Zepbound [8].

Most patients tolerate the schedule without needing to pause escalation, though gastrointestinal side effects (nausea in 30 to 40% of participants, vomiting in 15 to 20%) are common in the first 8 to 12 weeks [3]. Slowing the escalation by extending any step to 8 weeks is a clinically accepted strategy for managing GI intolerance, though this delays reaching the therapeutic weight-loss dose.

The target maintenance dose for OSA benefit is likely 10 to 15 mg weekly. The 5 mg dose, which is a transitional step, was not studied as a maintenance dose in SURMOUNT-OSA.

Practical Prescribing Considerations

Clinicians prescribing tirzepatide off-label for OSA should document the following in the chart:

1. The off-label nature of the prescription and the evidence basis (SURMOUNT-OSA publication).
2. Informed consent discussion including the off-label status, known side effects, and the requirement for periodic sleep studies.
3. The primary coded diagnosis (obesity or type 2 diabetes) for prescription and insurance purposes.
4. A monitoring plan with scheduled follow-up intervals.
5. Coordination with the patient's sleep medicine team, if one exists.

Prescribing tirzepatide without a baseline sleep study, or without a plan to repeat one, falls below the standard of care when OSA management is the therapeutic goal. A prescription written solely for weight management does not require these additional steps, but once OSA improvement is cited as a treatment rationale, the monitoring obligations change.

The American Thoracic Society position on pharmacologic adjuncts to CPAP (ATS) [11] states that weight loss interventions can be offered alongside PAP therapy but should not delay initiation of PAP in patients with severe OSA or significant oxygen desaturation. Patients with AHI above 30 events per hour, or with oxygen saturation nadir below 80%, should continue or start CPAP while tirzepatide takes effect over the following 6 to 12 months.